RxDoctor Payments Data

Henry Porter, MD

Neurology · Pensacola, FLNPI 1811989346

Payments from drug & device makers

$32,600in general payments, 2019–2025

Across 1,699 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Jazz Pharmaceuticals Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Pfizer$1K
  • Novartis$1K
  • MDD US Operations, LLC$1K
  • plus $21K from 54 others

What the payments were for

  • Travel & lodging$7352%
  • Food & beverage$31,46097%
  • Education$4061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)265$3,379
Jazz Pharmaceuticals Inc.89$2,047
Teva Pharmaceuticals USA, Inc.58$1,424
Pfizer136$1,409
Novartis85$1,334
MDD US Operations, LLC19$1,288
SK Life Science, Inc.53$1,238
Livanova USA, Inc.12$1,224
UCB, Inc.64$1,103
Biogen74$1,094
Lundbeck LLC42$999
Eisai Inc.45$934
Amgen(2 entities)52$923
AstraZeneca(2 entities)33$746
Genentech USA, Inc.40$733
Lilly USA, LLC42$731
EMD Serono, Inc.41$720
Argenx US, Inc.22$691
Acadia Pharmaceuticals Inc29$519
CSL Behring14$500
Catalyst Pharmaceuticals, Inc.19$472
Sunovion Pharmaceuticals Inc.27$413
Bristol Myers Squibb9$391
Otsuka America Pharmaceutical, Inc.14$389
Neurocrine Biosciences, Inc.18$383
Alnylam Pharmaceuticals Inc.18$381
Acorda Therapeutics, Inc20$380
Mallinckrodt Hospital Products Inc.17$375
Takeda Pharmaceuticals U.S.A., Inc.22$370
Axsome Therapeutics, Inc.16$363
Impel Pharmaceuticals Inc.30$338
Octapharma USA, Inc.13$310
Merz Pharmaceuticals, LLC12$280
Adamas Pharmaceuticals, Inc.13$267
Sanofi14$262
Supernus Pharmaceuticals, Inc.14$251
Greenwich Biosciences, Inc.8$238
Grifols USA, LLC11$217
Neurelis, Inc.9$179
Merck11$178
E.r. Squibb & Sons, L.L.C.5$172
Amneal Pharmaceuticals LLC11$170
Biohaven Pharmaceutical Holding Company Ltd.12$169
Harmony Biosciences LLC10$168
Akcea Therapeutics, Inc.6$159
Kyowa Kirin, Inc.9$154
Tanabe Pharma America, Inc.9$149
Avanir Pharmaceuticals, Inc.7$128
Biohaven Pharmaceuticals, Inc.8$124
Johnson & Johnson(2 entities)6$119
Philips North America LLC4$119
Inspire Medical Systems, Inc.3$102
Xeris Pharmaceuticals, Inc.6$99
Mallinckrodt Enterprises LLC6$98
Upsher-smith Laboratories LLC6$91
Arbor Pharmaceuticals, Inc.5$88
GE HealthCare4$86
Averitas Pharma Inc.5$83
Medtronic(2 entities)4$82
Avadel CNS Pharmaceuticals, LLC3$76

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,600 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$450,070
Medicare patients
948
Services billed
32,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5041$586,701
XywavSodium,calcium,mag,pot Oxybate24$482,119
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$360,133
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5013$274,697
AustedoDeutetrabenazine24$265,783
Nurtec OdtRimegepant Sulfate159$214,493
CopaxoneGlatiramer Acetate19$155,572
NuplazidPimavanserin Tartrate28$137,311
EpidiolexCannabidiol (Cbd)27$128,681
Gamunex-CImmune Globul G/Gly/Iga Avg 4616$110,866
VumerityDiroximel Fumarate11$106,348
XcopriCenobamate63$87,954
Emgality PenGalcanezumab-Gnlm83$76,553
FycompaPerampanel35$48,281
QuliptaAtogepant33$44,211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$1,424$421,35543 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$370$360,13326 claims
CSL BehringPrivigen$500$274,69713 claims
PfizerNurtec Odt, Lyrica, Eliquis$1,409$235,397190 claims
Acadia Pharmaceuticals IncNuplazid$519$137,31128 claims
Grifols USA, LLCGamunex-C$217$110,86616 claims
BiogenVumerity$1,094$106,34811 claims
SK Life Science, Inc.Xcopri$1,238$87,95463 claims
AbbVieQulipta, Ubrelvy$3,379$87,50568 claims
Eisai Inc.Fycompa$934$48,28135 claims
UCB, Inc.Neupro, Nayzilam$1,103$43,38542 claims
Otsuka America Pharmaceutical, Inc.Rexulti$389$41,21532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.

Other neurology in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →